Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000323 · ClinicalTrials.gov registry record
Therapeutic Potential of Kappa-Opioids Against Cocaine - 1
A clinical trial of Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT00000323 is a study of Cocaine-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 10 participants, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00000323, a study of Cocaine-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.
Conditions Studied
Study Locations (1)
Maryland
- Johns Hopkins University (BPRU) Bayview Campus - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1996-07 |
| Est. Completion | 1998-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000323
The ClinicalTrials.gov registry entry for NCT00000323 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (84% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 0 interventions.
NCT00000323 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00000323 about?
NCT00000323 is a clinical study titled "Therapeutic Potential of Kappa-Opioids Against Cocaine - 1". The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.
What is the current status of trial NCT00000323?
This trial is currently completed. The enrollment target is 10 participants. The study started on 1996-07. Estimated completion is 1998-12.
What conditions does trial NCT00000323 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders.
Who is sponsoring clinical trial NCT00000323?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000323 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Progesterone for the Treatment of Cocaine Dependence - 1
COMPLETED · NA
-
Modeling Impaired Judgement in Cocaine Abusers - 6
COMPLETED · Phase 4
-
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
COMPLETED · Phase 2
-
Quetiapine for Cocaine Use and Cravings
COMPLETED · Phase 4
-
Dose Response Trial of Pergolide for Cocaine Dependence - 1
COMPLETED · Phase 3
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.